171 related articles for article (PubMed ID: 25881192)
1. Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D).
Heywood J; Evangelou M; Goymer D; Kennet J; Anselmiova K; Guy C; O'Brien C; Nutland S; Brown J; Walker NM; Todd JA; Waldron-Lynch F
Trials; 2015 Mar; 16():86. PubMed ID: 25881192
[TBL] [Abstract][Full Text] [Related]
2. Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial.
Waldron-Lynch F; Kareclas P; Irons K; Walker NM; Mander A; Wicker LS; Todd JA; Bond S
BMJ Open; 2014 Jun; 4(6):e005559. PubMed ID: 24898091
[TBL] [Abstract][Full Text] [Related]
3. Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.
Todd JA; Evangelou M; Cutler AJ; Pekalski ML; Walker NM; Stevens HE; Porter L; Smyth DJ; Rainbow DB; Ferreira RC; Esposito L; Hunter KM; Loudon K; Irons K; Yang JH; Bell CJ; Schuilenburg H; Heywood J; Challis B; Neupane S; Clarke P; Coleman G; Dawson S; Goymer D; Anselmiova K; Kennet J; Brown J; Caddy SL; Lu J; Greatorex J; Goodfellow I; Wallace C; Tree TI; Evans M; Mander AP; Bond S; Wicker LS; Waldron-Lynch F
PLoS Med; 2016 Oct; 13(10):e1002139. PubMed ID: 27727279
[TBL] [Abstract][Full Text] [Related]
4. Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study.
Truman LA; Pekalski ML; Kareclas P; Evangelou M; Walker NM; Howlett J; Mander AP; Kennet J; Wicker LS; Bond S; Todd JA; Waldron-Lynch F
BMJ Open; 2015 Dec; 5(12):e009799. PubMed ID: 26646829
[TBL] [Abstract][Full Text] [Related]
5. The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes.
Seelig E; Howlett J; Porter L; Truman L; Heywood J; Kennet J; Arbon EL; Anselmiova K; Walker NM; Atkar R; Pekalski ML; Rytina E; Evans M; Wicker LS; Todd JA; Mander AP; Bond S; Waldron-Lynch F
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282826
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study.
Rosenzwajg M; Salet R; Lorenzon R; Tchitchek N; Roux A; Bernard C; Carel JC; Storey C; Polak M; Beltrand J; Amouyal C; Hartemann A; Corbeau P; Vicaut E; Bibal C; Bougnères P; Tran TA; Klatzmann D
Diabetologia; 2020 Sep; 63(9):1808-1821. PubMed ID: 32607749
[TBL] [Abstract][Full Text] [Related]
8. Recruitment and retention of participants for an international type 1 diabetes prevention trial: a coordinators' perspective.
Franciscus M; Nucci A; Bradley B; Suomalainen H; Greenberg E; Laforte D; Kleemola P; Hyytinen M; Salonen M; Martin MJ; Catte D; Catteau J;
Clin Trials; 2014 Apr; 11(2):150-8. PubMed ID: 24216218
[TBL] [Abstract][Full Text] [Related]
9. Recruitment of men to a multi-centre diabetes prevention trial: an evaluation of traditional and online promotional strategies.
Bracken K; Hague W; Keech A; Conway A; Handelsman DJ; Grossmann M; Jesudason D; Stuckey B; Yeap BB; Inder W; Allan C; McLachlan R; Robledo KP; Wittert G
Trials; 2019 Jun; 20(1):366. PubMed ID: 31217024
[TBL] [Abstract][Full Text] [Related]
10. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial.
Hartemann A; Bensimon G; Payan CA; Jacqueminet S; Bourron O; Nicolas N; Fonfrede M; Rosenzwajg M; Bernard C; Klatzmann D
Lancet Diabetes Endocrinol; 2013 Dec; 1(4):295-305. PubMed ID: 24622415
[TBL] [Abstract][Full Text] [Related]
11. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes.
Dong S; Hiam-Galvez KJ; Mowery CT; Herold KC; Gitelman SE; Esensten JH; Liu W; Lares AP; Leinbach AS; Lee M; Nguyen V; Tamaki SJ; Tamaki W; Tamaki CM; Mehdizadeh M; Putnam AL; Spitzer MH; Ye CJ; Tang Q; Bluestone JA
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34324441
[TBL] [Abstract][Full Text] [Related]
12. Undertaking Studies Within A Trial to evaluate recruitment and retention strategies for randomised controlled trials: lessons learnt from the PROMETHEUS research programme.
Parker A; Arundel C; Clark L; Coleman E; Doherty L; Hewitt CE; Beard D; Bower P; Cooper C; Culliford L; Devane D; Emsley R; Eldridge S; Galvin S; Gillies K; Montgomery A; Sutton CJ; Treweek S; Torgerson DJ
Health Technol Assess; 2024 Jan; 28(2):1-114. PubMed ID: 38327177
[TBL] [Abstract][Full Text] [Related]
13. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
14. Internet-Based Recruitment and Retention of Young Adults With Type 1 Diabetes: Cross-Sectional Study.
Griggs S; Ash GI; Pignatiello G; Papik A; Huynh J; Leuchtag M; Hickman RL
JMIR Form Res; 2023 Aug; 7():e46415. PubMed ID: 37606985
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy.
Perais J; Agarwal R; Evans JR; Loveman E; Colquitt JL; Owens D; Hogg RE; Lawrenson JG; Takwoingi Y; Lois N
Cochrane Database Syst Rev; 2023 Feb; 2(2):CD013775. PubMed ID: 36815723
[TBL] [Abstract][Full Text] [Related]
16. Exposure to DDT metabolite p,p'-DDE increases autoimmune type 1 diabetes incidence in NOD mouse model.
Cetkovic-Cvrlje M; Olson M; Schindler B; Gong HK
J Immunotoxicol; 2016; 13(1):108-18. PubMed ID: 25721050
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of the effectiveness of recruitment methods: the staying well after depression randomized controlled trial.
Krusche A; Rudolf von Rohr I; Muse K; Duggan D; Crane C; Williams JM
Clin Trials; 2014 Apr; 11(2):141-9. PubMed ID: 24686105
[TBL] [Abstract][Full Text] [Related]
18. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.
Rosenzwajg M; Churlaud G; Mallone R; Six A; Dérian N; Chaara W; Lorenzon R; Long SA; Buckner JH; Afonso G; Pham HP; Hartemann A; Yu A; Pugliese A; Malek TR; Klatzmann D
J Autoimmun; 2015 Apr; 58():48-58. PubMed ID: 25634360
[TBL] [Abstract][Full Text] [Related]
19. Social media and internet driven study recruitment: evaluating a new model for promoting collaborator engagement and participation.
Khatri C; Chapman SJ; Glasbey J; Kelly M; Nepogodiev D; Bhangu A; Fitzgerald JE;
PLoS One; 2015; 10(3):e0118899. PubMed ID: 25775005
[TBL] [Abstract][Full Text] [Related]
20. Comparison of characteristics and outcomes by initial study contact (website versus staff) for participants enrolled in a weight management study.
Funk KL; Elder CR; Lindberg NM; Gullion CM; DeBar LL; Meltesen G; Stevens VJ
Clin Trials; 2012 Apr; 9(2):226-31. PubMed ID: 22273589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
